Literature DB >> 28964382

Emergency Department, Hospital Inpatient, and Mortality Burden of Atrial Fibrillation in the United States, 2006 to 2014.

Sandra L Jackson1, Xin Tong2, Xiaoping Yin2, Mary G George2, Matthew D Ritchey2.   

Abstract

The prevalence of atrial fibrillation (AF) is increasing in the United States as the population ages, but national surveillance is lacking. This cross-sectional study (2006 to 2014) analyzed data from the Healthcare Cost and Utilization Project's Nationwide Emergency Department Sample, the National (Nationwide) Inpatient Sample, and the National Vital Statistics System. Event totals were estimated independently for emergency department (ED) visits, hospitalizations, and mortality, and then collectively after applying criteria to identify mutually exclusive events. Rates were calculated for AF as primary diagnosis or underlying cause of death (primary AF), as well as secondary diagnosis or contributing cause of death (co-morbid AF), and standardized by age to the 2010 US population. From 2006 to 2014, event rates increased for primary AF (249 to 268 per 100,000) and co-morbid AF (1,473 to 1,835 per 100,000). In 2014, an estimated 599,790 ED visits, 453,060 hospitalizations, and 21,712 deaths listed AF as primary. A total of 684,470 mutually exclusive primary AF and 4,695,997 mutually exclusive co-morbid AF events occurred. Among ED visits and hospitalizations with primary AF, the most common secondary diagnoses were hypertension, heart failure, ischemic heart disease, and diabetes. The mean cost per hospitalization with primary AF was $8,819. Mean costs were higher for those with co-morbid AF versus those without co-morbid AF among hospitalizations with a primary diagnosis of ischemic heart disease, heart failure, stroke, hypertension, or diabetes (all p ≤0.01). In conclusion, with the substantial health and economic impact of AF and an aging US population, improved diagnosis, prevention, management, and surveillance of AF are increasingly important. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2017        PMID: 28964382      PMCID: PMC6485413          DOI: 10.1016/j.amjcard.2017.08.017

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  9 in total

1.  Vaccination and risk of lone atrial fibrillation in the active component United States military.

Authors:  Michael M McNeil; Susan K Duderstadt; Jennifer F Sabatier; Gina G Ma; Jonathan Duffy
Journal:  Hum Vaccin Immunother       Date:  2019-01-08       Impact factor: 3.452

2.  National Burden of Heart Failure Events in the United States, 2006 to 2014.

Authors:  Sandra L Jackson; Xin Tong; Raymond J King; Fleetwood Loustalot; Yuling Hong; Matthew D Ritchey
Journal:  Circ Heart Fail       Date:  2018-12       Impact factor: 8.790

3.  Artificial intelligence MacHIne learning for the detection and treatment of atrial fibrillation guidelines in the emergency department setting (AIM HIGHER): Assessing a machine learning clinical decision support tool to detect and treat non-valvular atrial fibrillation in the emergency department.

Authors:  Kim Schwab; Dacloc Nguyen; GilAnthony Ungab; Gregory Feld; Alan S Maisel; Martin Than; Laura Joyce; W Frank Peacock
Journal:  J Am Coll Emerg Physicians Open       Date:  2021-08-09

4.  Temporal Trends of Emergency Department Visits of Patients with Atrial Fibrillation: A Nationwide Population-Based Study.

Authors:  So-Ryoung Lee; Eue-Keun Choi; Seo-Young Lee; Euijae Lee; Kyung-Do Han; Myung-Jin Cha; Woon Yong Kwon; Sang Do Shin; Seil Oh; Gregory Y H Lip
Journal:  J Clin Med       Date:  2020-05-14       Impact factor: 4.241

5.  The Burden of Cerebrovascular Disease in the United States.

Authors:  Xin Tong; Quanhe Yang; Matthew D Ritchey; Mary G George; Sandra L Jackson; Cathleen Gillespie; Robert K Merritt
Journal:  Prev Chronic Dis       Date:  2019-04-25       Impact factor: 2.830

6.  Assessment of cardiac biomarkers (troponin, B-type natriuretic peptide, and D-dimer) in patients with non-valvular atrial fibrillation and stroke.

Authors:  Bilonda K Paulin; Kabulo K Cedric; Abdelhakam G Tamomh; Yang Dong Hui
Journal:  Int J Health Sci (Qassim)       Date:  2019 Nov-Dec

7.  Impact of a Multidisciplinary Treatment Pathway for Atrial Fibrillation in the Emergency Department on Hospital Admissions and Length of Stay: Results of a Multi-Center Study.

Authors:  Leon M Ptaszek; Christopher W Baugh; Steven A Lubitz; Jeremy N Ruskin; Grace Ha; Margaux Forsch; Samer A DeOliveira; Samia Baig; E Kevin Heist; Jason H Wasfy; David F Brown; Paul D Biddinger; Ali S Raja; Benjamin Scirica; Benjamin A White; Moussa Mansour
Journal:  J Am Heart Assoc       Date:  2019-09-12       Impact factor: 5.501

8.  Polypharmacy and health outcomes in atrial fibrillation: a systematic review and meta-analysis.

Authors:  Celine Gallagher; Karin Nyfort-Hansen; Debra Rowett; Christopher X Wong; Melissa E Middeldorp; Rajiv Mahajan; Dennis H Lau; Prashanthan Sanders; Jeroen M Hendriks
Journal:  Open Heart       Date:  2020-04-06

9.  Apelin increases atrial conduction velocity, refractoriness, and prevents inducibility of atrial fibrillation.

Authors:  Young M Kim; Robert Lakin; Hao Zhang; Jack Liu; Ayaaz Sachedina; Maneesh Singh; Emily Wilson; Marco Perez; Subodh Verma; Thomas Quertermous; Jeffrey Olgin; Peter H Backx; Euan A Ashley
Journal:  JCI Insight       Date:  2020-09-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.